# Losartan

Drug · id `cardio:losartan` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

Also called: Cozaar; Losartan potassium

Browse, organ or system: Blood vessels; Brain; Kidneys  
Browse, condition area: High blood pressure; Stroke; Kidney connections  

## In plain language

Losartan is an ARB (angiotensin II receptor blocker), a medicine taken by mouth. The US label read, for COZAAR tablets (losartan potassium), lists three uses: treating high blood pressure in adults and children, reducing the risk of stroke in patients with high blood pressure and left ventricular hypertrophy (the label says this benefit does not apply to Black patients), and treating diabetic nephropathy in patients with type 2 diabetes and a history of high blood pressure. Cozaar is the brand name on the label read.

## Technical summary

RxNorm ingredient 52175; UNII 3ST302B24A. The label names the substance as losartan potassium, so UNII 3ST302B24A is the UNII of the potassium salt and is a broad match. MeSH descriptor D019808 is Losartan. Class: Angiotensin 2 Receptor Blocker (FDA established pharmacologic class, RxClass). The label read is the Organon LLC label for COZAAR (losartan potassium) tablets, application NDA020386, effective 2026-01-20 in openFDA; Drugs@FDA lists the application's sponsor as ORGANON. Other losartan labels, including generic products and fixed combinations with hydrochlorothiazide, were not read. This page records label indications and the class only: no trial result and no dose is given.

## Claims, with the population each applies to

## Context: Patients for whom the US label of losartan (Cozaar) lists an indication: adult hypertension, stroke risk reduction with hypertension and left ventricular hypertrophy, diabetic nephropathy in type 2 diabetes

Recipient: Recipient not specified; Population: Patients described in the indications section of the label. The hypertension indication names adults (and, separately, children); the stroke and diabetic nephropathy indications do not state an age range.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Adults for hypertension, as the passage read states; not stated for the other indications; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)

### The US label of COZAAR (losartan potassium) tablets, in the Organon LLC version dated 2026-01-20 in openFDA, lists the medicine for the treatment of hypertension, to lower blood pressure in adults (the same label sentence also names children, recorded separately); for reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy, with the label stating that there is evidence this benefit does not apply to Black patients; and for the treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria in patients with type 2 diabetes and a history of hypertension.

- Category: Description
- Evidence stage: Evidence stage not applicable
- Certainty: Certainty not assessed
- Applies to: Recipient: Recipient not specified; Population: Patients described in the indications section of the label. The hypertension indication names adults (and, separately, children); the stroke and diabetic nephropathy indications do not state an age range.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Adults for hypertension, as the passage read states; not stated for the other indications; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)
- Limitations: This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label may list other indications that were not recorded. Contraindications, doses, interactions and warnings were not read, and the label has a boxed warning section whose content was not read or recorded. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked: 2026-11-09
- Sources:
  1. Supports: openFDA drug label record for COZAAR (losartan potassium tablets), Organon LLC label: indications and class description (Regulator, edition The openFDA drug label record for set id 9949448f-c3b9-44ee-94ed-c1aca8c90f39 (manufacturer Organon LLC, application NDA020386), returned on 2026-11-09. The label text is dated 2026-01-20 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%229949448f-c3b9-44ee-94ed-c1aca8c90f39%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\], 1 INDICATIONS AND USAGE. Retrieved 2026-11-09T13:17:34Z. Source state: Current. Version fingerprint: 536990a875d291986fb51dbf7b10cf8ee959b18f260426b2261c43216a2378f9.
     How it applies: The label sentences that give the indications named in the statement, each quoted in the research quote table.
  2. Background: openFDA drug label record for COZAAR (losartan potassium tablets), Organon LLC label: indications and class description (Regulator, edition The openFDA drug label record for set id 9949448f-c3b9-44ee-94ed-c1aca8c90f39 (manufacturer Organon LLC, application NDA020386), returned on 2026-11-09. The label text is dated 2026-01-20 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%229949448f-c3b9-44ee-94ed-c1aca8c90f39%22&limit=1>
     Locator: results\[0\].effective\_time. Retrieved 2026-11-09T13:17:34Z. Source state: Current. Version fingerprint: 536990a875d291986fb51dbf7b10cf8ee959b18f260426b2261c43216a2378f9.
     How it applies: Effective date of the label text read, 20260120.
  3. Background: openFDA Drugs@FDA record for application NDA020386 (COZAAR, sponsor ORGANON): product and sponsor (Regulator, edition The openFDA Drugs@FDA record for application NDA020386, returned on 2026-11-09. It lists the sponsor and the products of the application; only the first product listing is quoted.) <https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA020386%22&limit=1>
     Locator: results\[0\].products\[0\].brand\_name. Retrieved 2026-11-09T13:20:29Z. Source state: Current. Version fingerprint: e0ad0edb3a20d7283469925ea923a9d98524b4ca8f423e4915a9465c019d4abc.
     How it applies: Drugs@FDA product listing for application NDA020386, which confirms the product the label belongs to.

## Context: Children for whom the US label of losartan (Cozaar) lists hypertension as an indication: children greater than 6 years old (highlights wording)

Recipient: Child; Population: Children with hypertension, as the indications section of the label describes them. The same label sentence also names adults, who are recorded in a separate context.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Label wording: children greater than 6 years old (highlights wording); Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)

### The US label of COZAAR (losartan potassium) tablets, in the Organon LLC version dated 2026-01-20 in openFDA, lists the medicine for the treatment of hypertension, to lower blood pressure, in children greater than 6 years old (the highlights wording; a later section of the same label says pediatric patients 6 years of age and older).

- Category: Description
- Evidence stage: Evidence stage not applicable
- Certainty: Certainty not assessed
- Applies to: Recipient: Child; Population: Children with hypertension, as the indications section of the label describes them. The same label sentence also names adults, who are recorded in a separate context.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Label wording: children greater than 6 years old (highlights wording); Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)
- Limitations: This claim records what the label says the medicine is indicated for in children. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label may list other indications that were not recorded. Contraindications, doses, interactions and warnings were not read, and the label has a boxed warning section whose content was not read or recorded. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked: 2026-11-09
- Sources:
  1. Supports: openFDA drug label record for COZAAR (losartan potassium tablets), Organon LLC label: indications and class description (Regulator, edition The openFDA drug label record for set id 9949448f-c3b9-44ee-94ed-c1aca8c90f39 (manufacturer Organon LLC, application NDA020386), returned on 2026-11-09. The label text is dated 2026-01-20 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%229949448f-c3b9-44ee-94ed-c1aca8c90f39%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\], 1 INDICATIONS AND USAGE. Retrieved 2026-11-09T13:17:34Z. Source state: Current. Version fingerprint: 536990a875d291986fb51dbf7b10cf8ee959b18f260426b2261c43216a2378f9.
     How it applies: The label sentence that names children in the hypertension indication, quoted in the research quote table.
  2. Background: openFDA drug label record for COZAAR (losartan potassium tablets), Organon LLC label: indications and class description (Regulator, edition The openFDA drug label record for set id 9949448f-c3b9-44ee-94ed-c1aca8c90f39 (manufacturer Organon LLC, application NDA020386), returned on 2026-11-09. The label text is dated 2026-01-20 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%229949448f-c3b9-44ee-94ed-c1aca8c90f39%22&limit=1>
     Locator: results\[0\].effective\_time. Retrieved 2026-11-09T13:17:34Z. Source state: Current. Version fingerprint: 536990a875d291986fb51dbf7b10cf8ee959b18f260426b2261c43216a2378f9.
     How it applies: Effective date of the label text read, 20260120.

## Connected pages

- Losartan is an ARB (FDA established pharmacologic class in RxClass): Angiotensin receptor blockers (ARBs) (`cardio:angiotensin-receptor-blockers-arbs`)
- FDA label lists hypertension as an indication: Hypertension (high blood pressure) (`core:hypertension`) [a claim, not a settled fact; see claim `cardio:claim-fda-losartan-label-indications` and its context]
- FDA label lists reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy as an indication, and says the benefit does not apply to Black patients: Stroke (`core:stroke`) [a claim, not a settled fact; see claim `cardio:claim-fda-losartan-label-indications` and its context]
- FDA label lists diabetic nephropathy with elevated serum creatinine and proteinuria in patients with type 2 diabetes and a history of hypertension as an indication: Diabetic kidney disease (`cardio:diabetic-nephropathy`) [a claim, not a settled fact; see claim `cardio:claim-fda-losartan-label-indications` and its context]
- Files under this front: Medicines (`cardio:front-medicines`)

## Registry records

Records a program assembled from a public registry; no person wrote or checked them. They are counted here, not listed: the JSON record of this page lists each one in its relationships.

- 3 registry products
- 21 registry trials

## Provenance

Content hash: e55023eb6ea78a13524e29bcb5f36174bb803fbd91fd4b872421f1285ee5537f
Last substantive edit: 2026-11-09
Evidence last checked: 2026-11-09
